Mold-fermented foods and mycelial extracts reshape the gut microbiome

Tempeh, Quorn, and koji-fermented grains have been dietary staples for centuries, but scientists are only beginning to map what they do inside the colon. A narrative review published in Gut Microbes by Keigler, Leite Nobrega de Moura Bell, and Marco synthesizes four human trials, eight animal studies, and eight in vitro experiments to ask a single sharp question: do myco-foods, meaning foods built from or fermented by molds, consistently change the gut microbiome? The answer, across every human trial examined, was yes.

Bifidobacterium, Akkermansia, and SCFAs all rose after myco-food intake

Every one of the four human trials in the review recorded measurable shifts in gut microbial communities. The most consistent winners were taxa already associated with metabolic and immune health: Bifidobacterium, Akkermansia, and lactobacilli increased frequently, and Bacteroides, Roseburia, and Eubacterium were also regularly enriched. Alongside those bacterial changes, numerous studies reported increases in fecal short-chain fatty acids (SCFAs), the fermentation byproducts that feed colonocytes, reinforce the gut lining, and dampen inflammation. One clinical trial linked a mycelial extract specifically to improved glucose and lipid metabolism, a finding that hints at systemic effects beyond the colon. The consistency across different mold species and food formats is striking; it suggests the microbiome response is not a quirk of one product but a property of the broader myco-food category.

Why fungal cell walls may be the active ingredient

The review points to two structural carbohydrates as the likely drivers: beta-glucans and chitin. Both are abundant in fungal cell walls and largely indigestible by human enzymes, which means they arrive in the colon intact, where resident bacteria compete to ferment them. Mushroom polysaccharides, including beta-glucans, are already known to regulate gut microbiota composition and boost short-chain fatty acid output, so the mechanism has precedent in closely related food systems. The review adds important species-level nuance: beta-glucan purified from Fusarium venenatum, the mold behind Quorn products, supported the growth of Bacteroides but not all Bifidobacterium strains. Chitin-glucan, by contrast, was utilized as a carbon source by Bifidobacterium animalis subsp. lactis BB-12, a well-characterized probiotic strain. That difference matters because it means the specific fungal species and the structural form of its polysaccharide determine which bacteria benefit most.

A cross-feeding loop also appears to amplify the response. Bifidobacterium and Lactiplantibacillus strains demonstrated growth on oligosaccharides released by Bacteroides during fermentation of mycelial material, suggesting that a primary fermentation event by one taxon unlocks substrate for another. This cascade may explain why the effects on microbiome diversity look broader than the direct substrate-utilization data would predict.

How the review weighed evidence across formats and species

Myco-foods span a wide range of formats: raw mycelial biomass, concentrated extracts, and whole mold-fermented foods like tempeh (made with Rhizopus), douchi (made with Aspergillus), and oncom (made with Neurospora). The review treated each format separately because the fermentation process itself transforms the food matrix, producing bioactive peptides, exopolysaccharides, and additional SCFAs before the product even reaches a consumer. Mold-fermented foods therefore arrive in the gut pre-loaded with bioactive compounds on top of whatever intact structural carbohydrates survived processing. The authors drew on methods used to characterize fungal communities in the gut mycobiome, where distinguishing fungal DNA from bacterial signals requires careful primer selection, to contextualize the in vitro findings. Animal and in vitro data were used to propose mechanisms rather than to make human health claims, a distinction the review is careful to maintain throughout.

The mycobiome itself, the community of fungi that permanently resides in the gut, sits in the background of this story. Emerging research shows that gut fungal communities modulate host immunity and physiology even though fungi constitute a small fraction of total gut microbiome biomass. Dietary myco-foods introduce transient fungal material and metabolites that may interact with this resident community in ways the current trials were not designed to measure.

Key gaps: metabolism of mycelial components remains poorly mapped

The review is honest about what remains unknown. All four human trials showed gut microbiome effects, but the sample sizes were small and the trial durations varied enough that dose-response relationships are impossible to pin down. More fundamentally, the metabolic fate of specific mycelial bioactives inside the colon is largely unmapped. Which enzymes do Bacteroides deploy to crack open fungal cell walls? What fermentation intermediates accumulate and disappear before fecal sampling? How does background diet interact with chitin and beta-glucan utilization? None of those questions has a clean answer yet. The authors also flag that the impact of diet on the gut mycobiome itself, including which mold-derived metabolites reach the colon intact after cooking or processing, represents a largely unexplored layer of complexity.

Therapeutic potential of myco-foods for microbiome-targeted diets

The consistency of the human trial results positions myco-foods as a credible dietary tool for microbiome modulation, not just a nutritional curiosity valued for protein and fiber. Insights into gut fungi are already opening avenues for developing therapeutics that shape microbial communities, including potential interventions for inflammatory bowel disease. Myco-foods sit at a useful intersection: they are whole foods with long safety records, they contain both prebiotic fiber and fermentation-derived metabolites, and they appear to selectively enrich taxa like Akkermansia and Bifidobacterium that are associated with healthy metabolic and immune function. The next step, according to Keigler and colleagues, is larger controlled trials that track fungal metabolite metabolism alongside bacterial community changes. Until that work is done, the precise levers connecting specific mold species to specific health outcomes will remain plausible but unproven. What the current evidence already establishes is that the fungal fraction of the food supply deserves far more scientific attention than it has historically received.